Literature DB >> 14598260

Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome.

Junlan Zhang1, Yiqun Ling, Bao Luo, Liping Tang, Stefan W Ryter, Cecil R Stockard, Willam E Grizzle, Michael B Fallon.   

Abstract

BACKGROUND & AIMS: Cirrhosis and portal hypertension due to chronic common bile duct ligation reproduce the features of human hepatopulmonary syndrome, whereas portal hypertension alone due to partial portal vein ligation does not. Nitric oxide contributes to experimental hepatopulmonary syndrome, but the nitric oxide synthase forms involved remain controversial. Recently, increased pulmonary heme oxygenase-1 expression and carbon monoxide production have also been found after common bile duct ligation. Our aim was to explore the role of the heme oxygenase-1/carbon monoxide pathway in the pathogenesis of experimental hepatopulmonary syndrome.
METHODS: Pulmonary heme oxygenase-1 expression and distribution were assessed in sham; 3-week partial portal vein ligation; and 1-, 2-, 3-, 4-, and 5-week common bile duct ligation animals by Northern, Western and immunohistochemical analysis relative to endothelial and inducible nitric oxide synthase levels and to hepatopulmonary syndrome development. In vivo heme oxygenase enzyme inhibition with tin protoporphyrin IX in common bile duct ligation animals was used to define effects on intrapulmonary vasodilatation and arterial blood gases.
RESULTS: Heme oxygenase-1 expression in pulmonary intravascular monocytes/macrophages and arterial carboxyhemoglobin levels increased progressively from 3 to 5 weeks after common bile duct ligation relative to controls (5-week protein levels were 15.94 +/- 1.75-fold those of sham animals; P < 0.001). Inducible nitric oxide synthase increased transiently in pulmonary intravascular monocytes/macrophages in 3-week common bile duct ligation animals, whereas pulmonary microvascular endothelial nitric oxide synthase increases began at 2 weeks and correlated with the onset of hepatopulmonary syndrome. Tin protoporphyrin treatment normalized carboxyhemoglobin and improved arterial blood gases and intrapulmonary vasodilatation, reflecting partial reversal of hepatopulmonary syndrome.
CONCLUSIONS: The heme oxygenase-1/carbon monoxide system is an important contributor to the progression of experimental hepatopulmonary syndrome in addition to alterations in the endothelial nitric oxide synthase/nitric oxide pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598260     DOI: 10.1016/j.gastro.2003.07.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

1.  Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans.

Authors:  David G Koch; Galina Bogatkevich; Venkat Ramshesh; John J Lemasters; Renan Uflacker; Adrian Reuben
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

2.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Pentoxifylline attenuation of experimental hepatopulmonary syndrome.

Authors:  Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; Balu K Chacko; Rakesh P Patel; Michael B Fallon
Journal:  J Appl Physiol (1985)       Date:  2006-11-16

Review 4.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

5.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

Review 6.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

7.  Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.

Authors:  Kari E Roberts; Steven M Kawut; Michael J Krowka; Robert S Brown; James F Trotter; Vijay Shah; Inga Peter; Hocine Tighiouart; Nandita Mitra; Elizabeth Handorf; James A Knowles; Steven Zacks; Michael B Fallon
Journal:  Gastroenterology       Date:  2010-03-24       Impact factor: 22.682

8.  The relationship between hepatopulmonary syndrome and altitude.

Authors:  Morgan A Valley; James F Trotter; Deborah Thomas; Adit A Ginde; Steven R Lownenstein; Benjamin Honigman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-03

Review 9.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

10.  Endothelial nitric oxide synthase regulation is altered in pancreas from cirrhotic rats.

Authors:  Jean-Louis Frossard; Rafael Quadri; Antoine Hadengue; Philippe Morel; Catherine M Pastor
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.